421 related articles for article (PubMed ID: 23416644)
1. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
[TBL] [Abstract][Full Text] [Related]
3. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
4. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
6. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
7. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
8. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
9. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
10. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster R; Andriole GL; Groskopf J
J Urol; 2010 Nov; 184(5):1947-52. PubMed ID: 20850153
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
12. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.
van Poppel H; Haese A; Graefen M; de la Taille A; Irani J; de Reijke T; Remzi M; Marberger M
BJU Int; 2012 Feb; 109(3):360-6. PubMed ID: 21883822
[TBL] [Abstract][Full Text] [Related]
13. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.
De Luca S; Passera R; Milillo A; Coda R; Randone DF
BJU Int; 2012 Dec; 110(11 Pt B):E778-82. PubMed ID: 23116408
[TBL] [Abstract][Full Text] [Related]
14. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
[TBL] [Abstract][Full Text] [Related]
15. [Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?].
Vinet M; Vlaeminck-Guillem V; Rouvière O; Perrin P; Paparel P; Devonec M; Adam E; Briant PE; Ruffion A
Prog Urol; 2013 Feb; 23(2):121-7. PubMed ID: 23352305
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
[TBL] [Abstract][Full Text] [Related]
18. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
19. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.
Chevli KK; Duff M; Walter P; Yu C; Capuder B; Elshafei A; Malczewski S; Kattan MW; Jones JS
J Urol; 2014 Jun; 191(6):1743-8. PubMed ID: 24333241
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
